HALOZYME THERAPEUTICS, INC. (HALO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 200M 400M 600M Q3 '21: 115.8M Q4 '21: 102M Q1 '22: 117.3M Q2 '22: 152.4M Q3 '22: 209M Q4 '22: 181.5M Q1 '23: 162.1M Q2 '23: 221M Q3 '23: 216M Q4 '23: 230M Q1 '24: 195.9M Q2 '24: 231.4M Q3 '24: 290.1M Q4 '24: 298M Q1 '25: 264.9M Q2 '25: 325.7M Q3 '25: 354.3M Q4 '25: 451.8M Q1 '26: 376.7M Q2 '26: 481M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 2.5M 5M 7.5M Q1 '16: 5.2M Q2 '16: 5.4M Q3 '16: 4.2M Q4 '16: 5.4M Q1 '17: 3.9M Q2 '17: 5M Q3 '17: 5.3M Q4 '17: 5.1M Q1 '18: 3.7M Q2 '18: 3.6M Q3 '18: 5.6M Q4 '18: 5.1M Q1 '19: 3.7M Q2 '19: 3.9M Q3 '19: 6.9M Q4 '19: 6M Q1 '20: 2.4M Q2 '20: 597K Q3 '20: 3.5M Q4 '20: 6.2M Q2 '16 Q1 '17 Q4 '17 Q3 '18 Q2 '19 Q1 '20 Q4 '20

Operating Income Quarterly

0 100M 200M 300M Q2 '21: 93M Q3 '21: 75.6M Q4 '21: 56.5M Q1 '22: 75.7M Q2 '22: 34.1M Q3 '22: 83.3M Q4 '22: 74.5M Q1 '23: 53.8M Q2 '23: 94.5M Q3 '23: 88.3M Q4 '23: 101M Q1 '24: 95.5M Q2 '24: 117.2M Q3 '24: 163.2M Q4 '24: 175.5M Q1 '25: 141.5M Q2 '25: 202.4M Q3 '25: 217.9M Q1 '26: 184.5M Q2 '26: 287.7M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Net Income Quarterly

0 80M 160M 240M Q2 '21: 91.5M Q3 '21: 216.6M Q4 '21: 66.8M Q1 '22: 60.1M Q2 '22: 22.7M Q3 '22: 61.6M Q4 '22: 57.7M Q1 '23: 39.6M Q2 '23: 74.8M Q3 '23: 81.8M Q4 '23: 85.4M Q1 '24: 76.8M Q2 '24: 93.2M Q3 '24: 137M Q4 '24: 137M Q1 '25: 118.1M Q2 '25: 165.2M Q3 '25: 175.2M Q1 '26: 150M Q2 '26: 229.9M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

0 30M 60M 90M Q3 '21: 18.6M Q4 '21: 21.6M Q1 '22: 15.9M Q2 '22: 33.9M Q3 '22: 47.3M Q4 '22: 42.1M Q1 '23: 35.2M Q2 '23: 50.1M Q3 '23: 54.8M Q4 '23: 52.3M Q1 '24: 28.3M Q2 '24: 39.6M Q3 '24: 49.4M Q4 '24: 42.1M Q1 '25: 48.4M Q2 '25: 46.4M Q3 '25: 55.2M Q4 '25: 78.8M Q1 '26: 79.2M Q2 '26: 79.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

0 90M 180M 270M Q3 '21: 121.7M Q4 '21: 82.5M Q1 '22: 47.8M Q2 '22: 40.2M Q3 '22: 69.6M Q4 '22: 82.5M Q1 '23: 87M Q2 '23: 66.8M Q3 '23: 132.4M Q4 '23: 102.4M Q1 '24: 129.4M Q2 '24: 55.8M Q3 '24: 115.4M Q4 '24: 178.5M Q1 '25: 154.2M Q2 '25: 99.7M Q3 '25: 178.6M Q4 '25: 219M Q1 '26: 180.1M Q2 '26: 240.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

0 90M 180M 270M Q3 '21: 121.2M Q4 '21: 82.4M Q1 '22: 47.3M Q2 '22: 39.3M Q3 '22: 68.6M Q4 '22: 80.1M Q1 '23: 75.6M Q2 '23: 65.2M Q3 '23: 129.5M Q4 '23: 99.8M Q1 '24: 125.9M Q2 '24: 53.2M Q3 '24: 113.9M Q4 '24: 175.4M Q1 '25: 153.3M Q2 '25: 98.1M Q3 '25: 175.6M Q4 '25: 217.6M Q1 '26: 176.3M Q2 '26: 236.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '20: 138.1M Q3 '20: 142.1M Q4 '20: 145.1M Q1 '21: 148.5M Q2 '21: 147.6M Q3 '21: 146.7M Q1 '22: 141.3M Q2 '22: 142.2M Q3 '22: 139.4M Q1 '23: 137.9M Q2 '23: 133.5M Q3 '23: 134.1M Q1 '24: 128.9M Q2 '24: 129.2M Q3 '24: 130.1M Q1 '25: 126.6M Q2 '25: 124.2M Q3 '25: 122.3M Q1 '26: 122.9M Q2 '26: 121.2M Q3 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 2.00 4.00 6.00 Q4 '20: 0.90 Q1 '21: 1.13 Q2 '21: 1.56 Q3 '21: 2.79 Q4 '21: 2.75 Q1 '22: 2.99 Q2 '22: 2.53 Q3 '22: 1.49 Q4 '22: 1.45 Q1 '23: 1.31 Q2 '23: 1.71 Q3 '23: 1.88 Q4 '23: 2.11 Q1 '24: 2.42 Q2 '24: 2.58 Q3 '24: 3.02 Q4 '24: 3.43 Q1 '25: 3.76 Q2 '25: 4.37 Q3 '25: 4.75 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.